isirv Antiviral Group
AVG Home
|
AVG Webinar Series
AVG Webinar series You can listen to the recordings from the AVG webinars which have taken place to date via the links below: 25 October 2022: Treatments/Antiviral Therapeutics - link to the recording 24 January 2023: Antiviral Resistance - link to the recording 20 June 2023: The Present and Future of Treatment Oriented Surveillance - link to the recording 30 Oct 2023: Challenges and Promise of Clinical Trials for Respiratory Antivirals - link to the recording 2024 ISIRV Webinars 24 Jan If you missed the webinar on 24 Jan on 'RSV Vaccination in the Elderly Population' you can register and watch the recording via this link 20 March If you missed this webinar on 'Emerging Influenza and the Human-Animal Interface' you can register and watch the recording via this link 29 May If you missed this webinar on ‘Recent antiviral developments for respiratory viral infections’ you can register and watch the recording via this link 18 June If you missed this webinar on ‘Bovine Influenza and other Hot Topics in Virus Evolution’ you can register and watch the recording via this link 5 Nov If you missed this webinar on 'Highlights from OPTIONS for the Control of Influenza XII' you can register and watch the recording via this link 7th AVG Conference (in-person)
We’ve had some great feedback….
AVG Overview
The isirv Antiviral Group (isirv-AVG) was established as a special interest group of isirv at the time of merger in April 2011 of the former Neuraminidase Inhibitor Susceptibility Network (NISN) with isirv. Its specific objectives are to promote understanding of the clinical use of antivirals against respiratory viruses, collate and provide up to date information on the emergence of antiviral resistance, and communicate expert commentary on preclinical and clinical development of potential novel/new antivirals. Read More
Latest… Genotypic and phenotypic susceptibility of emerging avian influenza A viruses to neuraminidase and cap-dependent endonuclease inhibitors… read more Detection of influenza A(H3N2) viruses with polymerase acidic subunit substitutions after and prior to baloxavir marboxil treatment during the 2022–2023 influenza season in Japan… read more Comparison of the Effectiveness of Baloxavir and Oseltamivir in Outpatients With Influenza B… read more Glycopolymer with Sulfated Fucose and 6'-Sialyllactose as a Dual-Targeted Inhibitor on Resistant Influenza A Virus Strains… read more Dual neutralization of influenza virus hemagglutinin and neuraminidase by a bispecific antibody leads to improved antiviral activity… read more
Antiviral News prepared by: Dr Jeremy C. Jones, Department of Infectious Diseases, St Jude Children’s Research Hospital, Memphis, TN, USA
|
Visit us on:
  Quick links:
Contact AVG:Email:avg@isirv.org |
